MDT-AP-0854
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 36.96
- os_event
- true
- age_years
- 10.1
- sex
- F
- new_clusters
- C1
- umap1_2d
- 5.260329766
- umap2_2d
- 0.972733325
- umap1_3d
- 0.919789058
- umap2_3d
- -2.67279004
- umap3_3d
- 0.218587952
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.370
- BILE_ACID_METABOLISM+0.310
- PROTEIN_SECRETION+0.280
- APICAL_SURFACE+0.190
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.180
- HEME_METABOLISM+0.150
- ADIPOGENESIS+0.140
- PEROXISOME+0.110
- KRAS_SIGNALING_DN+0.100
- FATTY_ACID_METABOLISM+0.080
Top 10 suppressed
- E2F_TARGETS-0.630
- G2M_CHECKPOINT-0.610
- MYC_TARGETS_V1-0.520
- MYC_TARGETS_V2-0.520
- WNT_BETA_CATENIN_SIGNALING-0.440
- MITOTIC_SPINDLE-0.420
- ANGIOGENESIS-0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- HEDGEHOG_SIGNALING-0.390
- TNFA_SIGNALING_VIA_NFKB-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0852 | Med | Medulloblastoma | 0.918 |
| 2 | ERR2598272 | fetal | fetal | 0.883 |
| 3 | ERR2598274 | fetal | fetal | 0.859 |
| 4 | MDT-AP-0009 | Med | Medulloblastoma | 0.847 |
| 5 | SRR975556 | — | — | 0.833 |
| 6 | ERR2598273 | fetal | fetal | 0.830 |
| 7 | BS_7BTZQKYY | EPN | EPN Tumor | 0.826 |
| 8 | 20040020.LumA | — | B | 0.825 |
| 9 | BS_7BTZQKYY | Ependymoma NOS | — | 0.824 |
| 10 | BS_9DZ253JY | pilocytic astrocytoma | — | 0.822 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.370 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.010 | Inavolisib | — uncovered |